Tiraboschi, C. D., Gentilini, L. D., Jaworski, F. M., Corapi, E. S., Velazquez, C., Chauchereau, A., . . . Compagno, D. G. (2019). Galectin-3 as a new negative checkpoint of the immune response is the key target for effective immunotherapy against prostate cancer. Web
Citación estilo ChicagoTiraboschi, Carolina Daniela, Lucas Daniel Gentilini, Felipe Martín Jaworski, Enrique Sebastian Corapi, Carla Velazquez, Anne Chauchereau, Diego Jose Laderach, and Daniel Georges Compagno. Galectin-3 As a New Negative Checkpoint of the Immune Response Is the Key Target for Effective Immunotherapy against Prostate Cancer. 2019.
Cita MLATiraboschi, Carolina Daniela, et al. Galectin-3 As a New Negative Checkpoint of the Immune Response Is the Key Target for Effective Immunotherapy against Prostate Cancer. 2019.